A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

Running, not enrolling · Phase 1/Phase 2

Conditions studied: Triple Negative Breast Neoplasms

In brief

This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer

Key facts

Study ID

NCT03742102

Run by

AstraZeneca

People needed

243

Starts

2018-12-21

Expected to finish

2027-02-26

Last updated by the study team

2026-08-04

Who can join

Age: 18 and older, up to 130. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female
• At least 18 years of age at the time of screening
• Patient must have locally confirmed advanced/unresectable or metastatic TNBC.
• No prior treatment for metastatic (Stage IV) TNBC
• Patient must have at least 1 lesion, not previously irradiated, that can be accurately measured
• WHO/ECOG status at 0 or 1 at enrollment
• Patients enrolled to Arm 6 (durvalumab and DS-8201a) Must provide documentation of locally determined advanced/unresectable or metastatic TNBC with HER2 low tumor expression (IHC 2+/ISH-, IHC 1+/ISH-, or IHC 1+/ISH untested)
• Patients enrolled in Arm 8 (durvalumab + Dato-DXd) Must have PD-L1 positive tumor as determined by an IHC based assay

You may not qualify if…

• History of allogeneic organ transplantation
• Active or prior documented autoimmune or inflammatory disorders
• Active infection including tuberculosis, hepatitis B (known positive HBV surface antigen [HBsAg] result), hepatitis C virus (HCV), or human immunodeficiency virus (positive HIV 1/2 antibodies)
• Untreated CNS metastases
• Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
• Any concurrent chemotherapy, IP, or biologic therapy for cancer treatment
• Female patients who are pregnant, breastfeeding
• Cardiac Ejection Fraction less than 50%
• Patients enrolled in Arm 2 only:
• Potent inhibitors or inducers or substrates of CYP3A4 or substrates of CYP2C9 or CYP2D6 within 2 weeks before the first dose of study treatment (3 weeks for St John's Wort)
• Diagnosis of diabetes mellitus Type I or diabetes mellitus Type II requiring insulin treatment.
• Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as heart failure, hypokalemia, potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age, or any concomitant medication known to prolong the QT interval
• Prior treatment with PI3K inhibitors, AKT inhibitors, or mammalian target of rapamycin (mTOR) inhibitors.
• Patients enrolled in Arm 5 only: History of venous thromboembolism in the past 3 months
• Patients enrolled in Arm 7 and 8 only: Clinically significant corneal disease in the opinion of the Investigator.
• Patients enrolled in Arm 6, 7 and 8 only:
• History of or active interstitial lung disease/pneumonitis
• Use of chloroquine or hydroxychloroquine in <14 days prior to Day 1 of DS-8201a (Arm 6) or Dato-DXd (DS-1062a; Arm 7 and 8) treatment
• Patients enrolled in Arm 6 only: Previously been diagnosed as HER2+ or received HER2-targeted therapy.

Where it is running

• Research Site — Tucson, Arizona, United States
• Research Site — Columbia, Maryland, United States
• Research Site — Boston, Massachusetts, United States
• Research Site — Boston, Massachusetts, United States
• Research Site — Grand Rapids, Michigan, United States
• Research Site — St Louis, Missouri, United States
• Research Site — Dallas, Texas, United States
• Research Site — Williamsburg, Virginia, United States
• Research Site — Kelowna, British Columbia, Canada
• Research Site — London, Ontario, Canada
• Research Site — Greenfield Park, Quebec, Canada
• Research Site — Montreal, Quebec, Canada
• Research Site — Gdansk, Poland
• Research Site — Krakow, Poland
• Research Site — Lublin, Poland
• Research Site — Opole, Poland
• Research Site — Rzeszów, Poland
• Research Site — Warsaw, Poland
• Research Site — Warsaw, Poland
• Research Site — Seoul, South Korea
• Research Site — Seoul, South Korea
• Research Site — Seoul, South Korea
• Research Site — Kaohsiung City, Taiwan
• Research Site — Taichung, Taiwan
• Research Site — Tainan, Taiwan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.